| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 1. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | olmesartan medoxomil/hydrochlorothiazide (Olmetec Plus®) |
| Formulation | 20 mg/12.5 mg, 20 mg/25 mg and 40 mg/12.5 mg film-coated tablet |
| Reference number | 227 |
| Indication | Treatment of essential hypertension where blood pressure is not adequately controlled by olmesartan medoxomil alone |
| Company | Daiichi Sankyo UK Ltd |
| BNF chapter | Cardiovascular system |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 10/01/2006 |